UofM Researchers Study Blood Pressure Drug Losartan in COVID-19 Patients

UofM Researchers Study Blood Pressure Drug Losartan in COVID-19 Patients

University of Minnesota Medical School researchers have launched two new clinical trials to test whether the blood pressure medication losartan can prevent lung injury in people recently diagnosed with COVID-19. 

One trial examines its efficacy in those hospitalized with COVID-19 pneumonia, the second its ability to prevent hospitalization in patients diagnosed with COVID-19. The trials are based on losartan’s effects on the hormone angiotensin II, which normally maintains blood pressure.

The novel coronavirus interferes with the mechanism that regulates the hormone’s level; this leads to high blood pressure and lung damage. Losartan, however, blocks the action of the hormone. The researchers hope this will counteract the effects of the excess angiotensin II and prevent lung damage in COVID-19 patients.

Trial Sites

The inpatient trial takes place in Minnesota at M Health Fairview hospitals and Hennepin County Medical Center (HCMC), as well as multiple sites nationwide. The outpatient arm of the trial will enroll patients at M Health Fairview hospitals, Mayo Clinic, and HCMC. 

More on Losartan

"Losartan has an established safety profile and is readily av...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee